IL295025A - Preparations and methods for the treatment of acute radiation syndrome - Google Patents

Preparations and methods for the treatment of acute radiation syndrome

Info

Publication number
IL295025A
IL295025A IL295025A IL29502522A IL295025A IL 295025 A IL295025 A IL 295025A IL 295025 A IL295025 A IL 295025A IL 29502522 A IL29502522 A IL 29502522A IL 295025 A IL295025 A IL 295025A
Authority
IL
Israel
Prior art keywords
seq
peptide
cells
pif
subject
Prior art date
Application number
IL295025A
Other languages
English (en)
Hebrew (he)
Original Assignee
Bioincept Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioincept Llc filed Critical Bioincept Llc
Publication of IL295025A publication Critical patent/IL295025A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
IL295025A 2014-09-16 2015-09-16 Preparations and methods for the treatment of acute radiation syndrome IL295025A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462051077P 2014-09-16 2014-09-16
US201562113298P 2015-02-06 2015-02-06
US201562211660P 2015-08-28 2015-08-28
PCT/US2015/050532 WO2016044493A1 (en) 2014-09-16 2015-09-16 Compositions and methods for treating acute radiation syndrome

Publications (1)

Publication Number Publication Date
IL295025A true IL295025A (en) 2022-09-01

Family

ID=55533820

Family Applications (2)

Application Number Title Priority Date Filing Date
IL295025A IL295025A (en) 2014-09-16 2015-09-16 Preparations and methods for the treatment of acute radiation syndrome
IL251108A IL251108B (en) 2014-09-16 2015-09-16 Preparations and methods for the treatment of acute radiation syndrome

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL251108A IL251108B (en) 2014-09-16 2015-09-16 Preparations and methods for the treatment of acute radiation syndrome

Country Status (8)

Country Link
US (4) US20170319645A1 (enExample)
EP (1) EP3193903A4 (enExample)
JP (2) JP6806685B2 (enExample)
CN (1) CN106999534A (enExample)
AU (3) AU2015317771A1 (enExample)
CA (1) CA2961375A1 (enExample)
IL (2) IL295025A (enExample)
WO (1) WO2016044493A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096987B2 (en) 2015-08-28 2021-08-24 Bioincept, Llc Mutant peptides and methods of treating subjects using the same
WO2017040186A1 (en) 2015-08-28 2017-03-09 Bioincept, Llc Compositions and methods for the treatment of neurodamage
WO2018156801A2 (en) * 2017-02-22 2018-08-30 Bioincept, Llc Peptides and methods of treating dystrophy-related disorders using the same
EP3655010A4 (en) * 2017-07-17 2021-06-09 Bioincept LLC PEPTIDES AND METHODS FOR TRANSPLANTATION AND RESTORATIVE ORGAN FUNCTION
WO2022047196A1 (en) * 2020-08-28 2022-03-03 Nisibis, Llc-S Pten inhibitors for treatment and prevention of bone marrow loss
WO2023056075A1 (en) * 2021-10-01 2023-04-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for reduced toxicity in transplantation using janus kinase (jak) inhibitors
EP4248985A1 (en) * 2022-03-25 2023-09-27 Consejo Superior de Investigaciones Científicas (CSIC) Peptides for the treatment of retinitis pigmentosa
WO2025117717A1 (en) * 2023-11-27 2025-06-05 The Brigham And Women’S Hospital, Inc. Skin based test for detection of radiation exposure

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4629722A (en) * 1984-07-12 1986-12-16 Ribi Immunochem Research, Inc. Method of inhibiting the onset of acute radiation syndrome
CA2584690C (en) * 2003-10-22 2015-10-06 Bioincept, Llc Pif peptides biologic activities, site of action, and the antibody to detect pif
US7723290B2 (en) * 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
US9737585B2 (en) * 2011-03-02 2017-08-22 Bioincept, Llc Compositions and methods for treatment of intracellular damage and bacterial infection
MX365403B (es) * 2012-01-09 2019-05-31 Serpin Pharma Llc Peptidos y metodos para usarlos.
CA2928411A1 (en) * 2013-10-22 2015-04-30 Bioincept, Llc Pif-transfected cells and methods of use

Also Published As

Publication number Publication date
EP3193903A1 (en) 2017-07-26
EP3193903A4 (en) 2018-03-14
JP6806685B2 (ja) 2021-01-06
IL251108A0 (en) 2017-04-30
AU2015317771A1 (en) 2017-04-06
US20260166120A1 (en) 2026-06-18
WO2016044493A1 (en) 2016-03-24
CN106999534A (zh) 2017-08-01
IL251108B (en) 2022-08-01
JP2021046432A (ja) 2021-03-25
US20220249595A1 (en) 2022-08-11
US20240350580A1 (en) 2024-10-24
JP2017529396A (ja) 2017-10-05
US12458681B2 (en) 2025-11-04
US20170319645A1 (en) 2017-11-09
AU2019202741A1 (en) 2019-05-16
CA2961375A1 (en) 2016-03-24
AU2021202310A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
US12458681B2 (en) Compositions and method for treating acute radiation syndrome
US12377054B2 (en) Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
Xue et al. The role of dendritic cells regulated by HMGB1/TLR4 signalling pathway in myocardial ischaemia reperfusion injury
Basler et al. Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy
US20140050728A1 (en) Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications
US10010577B2 (en) Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
Wang et al. IFNγ blockade in capillary leak site improves tumour chemotherapy by inhibiting lactate-induced endocytosis of vascular endothelial-cadherins
US10086070B2 (en) Combined therapy of alpha-1-antitrypsin and temporal T-cell depletion for preventing graft rejection
US20250025484A1 (en) Polymersome nanoparticles exhausting intracelluar amino acid for cancer therapy and methods thereof
CA2691415A1 (en) Tpp ii inhibitors for use in the treatment of autoimmune and inflammatory diseases and transplant rejection
CN110869044A (zh) 肽和用肽治疗营养不良相关病症的方法
Wen et al. Mitochondrial transplantation—a novel therapeutic strategy for erectile dysfunction: a narrative review
Sawada et al. Experimental studies on protective effects of FK506 against hepatic ischemia-reperfusion injury
Mineo et al. Islet and pancreas transplantation
HK40093107A (en) Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
Gallon et al. ERYTROPOIETIN ADMINISTRATION PROTECTS FROM CHRONIC ALLOGRAFT NEPHROPATHY IN A RAT MODEL OF KIDNEY TRANSPLANTATION.
Badiwala et al. 489: Cilostazol as an Adjunct to Cyclosporine Prevents Neointimal Hyperplasia after Vascular Injury